Jeffrey D. Neidhart

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Carlos Salama, Jian Han, Linda Yau et al. · New England Journal of Medicine · 2020 · 1.3K citations · Full text

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

Glen J. Weiss, Joseph Chao, Jeffrey D. Neidhart et al. · Investigational New Drugs · 2013 · 219 citations · Full text

Oncology, Polymer-drug Conjugate, Medicine +7

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 152 citations · Full text

Lymphoid Neoplasia, End-of-induction Pet Response, Medicine +7

Randomized Trial of Doxorubicin, Bisantrene, and Miltoxantrone in Advanced Breast Cancer: A Southwest Oncology Group Study

John D. Cowan, Jeffrey D. Neidhart, Suzanne McClure et al. · JNCI Journal of the National Cancer Institute · 1991 · 76 citations

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer

Edward B. Garon, Jeffrey D. Neidhart, Nashar Y Gabrail et al. · OncoTargets and Therapy · 2016 · 58 citations · Full text